CU20180159A7 - DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS - Google Patents

DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS

Info

Publication number
CU20180159A7
CU20180159A7 CU2018000159A CU20180159A CU20180159A7 CU 20180159 A7 CU20180159 A7 CU 20180159A7 CU 2018000159 A CU2018000159 A CU 2018000159A CU 20180159 A CU20180159 A CU 20180159A CU 20180159 A7 CU20180159 A7 CU 20180159A7
Authority
CU
Cuba
Prior art keywords
bordetella pertussis
synthetic
oligosaccharids
derivatives
vaccine against
Prior art date
Application number
CU2018000159A
Other languages
Spanish (es)
Inventor
Guangwu Chen
Guo Lina
Fenández Castillo Sonsire
Guillermo Vérez Bencomo Vicente
Original Assignee
Chengdu Olisynn Biotechnology Co Ltd
Inst Finlay De Vacunas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Olisynn Biotechnology Co Ltd, Inst Finlay De Vacunas filed Critical Chengdu Olisynn Biotechnology Co Ltd
Priority to CU2018000159A priority Critical patent/CU20180159A7/en
Priority to PCT/CU2019/050001 priority patent/WO2020135898A1/en
Priority to CN201980000706.9A priority patent/CN111819184B/en
Publication of CU20180159A7 publication Critical patent/CU20180159A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

<p>La presente invención proporciona fragmentos de oligosacáridos sintéticos provenientes del pentasacárido terminal del lipooligosacárido de Bordetella pertussis, un método para obtener los fragmentos de oligosacáridos sintéticos y los conjugados a partir de los mismos. También proporciona las composiciones vacunales que contienen tales glicoconjugados y que inducen una respuesta inmune capaz de reducir la colonización nasofaríngea de Bordetella pertussis.</p><p> The present invention provides synthetic oligosaccharide fragments derived from the terminal pentasaccharide of the Bordetella pertussis lipooligosaccharide, a method for obtaining the synthetic oligosaccharide fragments and the conjugates therefrom. It also provides the vaccine compositions that contain such glycoconjugates and that induce an immune response capable of reducing the nasopharyngeal colonization of Bordetella pertussis. </p>

CU2018000159A 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS CU20180159A7 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU2018000159A CU20180159A7 (en) 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS
PCT/CU2019/050001 WO2020135898A1 (en) 2018-12-28 2019-04-08 Synthetic oligosaccharide derivatives as a vaccine against bordetella pertussis
CN201980000706.9A CN111819184B (en) 2018-12-28 2019-04-08 Synthetic oligosaccharide derivatives as vaccine against bordetella pertussis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2018000159A CU20180159A7 (en) 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS

Publications (1)

Publication Number Publication Date
CU20180159A7 true CU20180159A7 (en) 2020-10-20

Family

ID=66793711

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000159A CU20180159A7 (en) 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS

Country Status (3)

Country Link
CN (1) CN111819184B (en)
CU (1) CU20180159A7 (en)
WO (1) WO2020135898A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL359179A1 (en) * 2000-06-02 2004-08-23 Pfizer Products Inc. Hygromycin a derivatives for the treatment of bacterial and protozoal infections
WO2012106251A2 (en) * 2011-01-31 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pertussis vaccine
PL404247A1 (en) * 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością LOS oligosugar Bordetella pertussis and pertussis toxin and its use in the prevention and treatment of infections caused by Bordetella pertussis
EP3242883A4 (en) * 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
US10076563B2 (en) * 2015-04-16 2018-09-18 Inventprise, Llc Bordetella pertussis immunogenic vaccine compositions

Also Published As

Publication number Publication date
CN111819184A (en) 2020-10-23
CN111819184B (en) 2024-01-12
WO2020135898A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
AR125320A2 (en) CRYSTALLINE COMPOUND, METHOD OF PREPARATION AND COMPOSITION INCLUDING IT
CO2017011245A2 (en) Group B streptococcus protein-polysaccharide conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates and their uses
CL2018000829A1 (en) Human anti-cd19 antibodies with high affinity
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
CO2020001927A2 (en) Production method of pharmaceutical compositions comprising the immunogenic chikungunya virus chikv-delta5nsp3
BR112019003577A2 (en) seed treatment methods and resulting products
BR112016023707A2 (en) method for producing l-amino acids using an alkaliphilic bacterium
BR112021012037A2 (en) Bifunctional anti-pd-1/il-7 molecule
UY33297A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT UNDERSTANDS AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME
BR112015018270A2 (en) compositions comprising 15-ohepa and methods of using them
BR112019003992A2 (en) neisseria meningitidis vaccine
BR112017004197A2 (en) Dengue virus disease vaccine compositions
EA201691915A1 (en) IMMUNOLOGICAL COMPOSITIONS, INCLUDING WEAKENED BY Histophilus somni
EA201990010A1 (en) INFECTIOUS Bronchitis Virus Vaccine
BR112017015288A2 (en) foot-and-mouth vaccine
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
UA116697C2 (en) Composition for preventing and curing mycoplasma infection
AR105010A1 (en) IMMUNOGEN COMPOSITIONS
PL404247A1 (en) LOS oligosugar Bordetella pertussis and pertussis toxin and its use in the prevention and treatment of infections caused by Bordetella pertussis
BR112017028224A2 (en) composition, and method for protecting a piglet against a pestivirus-associated disease.
MX2016009888A (en) Method for the treatment or prevention of infection-related immune conditions using a composition comprising igm.
WO2019017499A3 (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
BR112022011945A2 (en) BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT